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Abstract: Over 90% of cancer deaths are due to cancer cells metastasizing into other organs. Invasion
is a prerequisite for metastasis formation. Thus, inhibition of invasion can be an efficient way to
prevent disease progression in these patients. This could be achieved by targeting the molecules
regulating invasion. One of these is an oncogenic transcription factor, Myeloid Zinc Finger 1 (MZF1).
Dysregulated transcription factors represent a unique, increasing group of drug targets that are
responsible for aberrant gene expression in cancer and are important nodes driving cancer malignancy.
Recent studies report of a central involvement of MZF1 in the invasion and metastasis of various solid
cancers. In this review, we summarize the research on MZF1 in cancer including its function and role
in lysosome-mediated invasion and in the expression of genes involved in epithelial to mesenchymal
transition. We also discuss possible means to target it on the basis of the current knowledge of its
function in cancer.
Keywords: cancer therapy; EMT; lysosome; lysosome-mediated invasion; MZF1; phosphorylation;
PAK4; SUMOylation; transcription factor; zinc finger
1. Transcription Factors as Drug Targets in Cancer
For a long time, steroid receptors, which are also known as ligand-activated transcription factors,
have been the main group of transcription factors targeted in anti-cancer treatments. During recent
years, other sequence-specific transcription factors have emerged as promising anti-cancer drug targets
and consequently, transcription factors have lost their status of being “undruggable”. This is especially
the case for zinc finger transcription factors, which is a large group of proteins with their own specific
DNA binding sequences. A good example of a cancer drug that targets a transcription factor is
thalidomide, an antiemetic drug from the 1950s that has been repurposed as a novel treatment against
hematological malignancies and which functions by inactivating zinc finger transcription factors
Ikarios (IKZF1) and Aiolos (IKZF3) through their destabilization [1,2]. Here we will summarize the
recent literature on the role and function of another cancer-relevant zinc finger transcription factor,
Myeloid Zinc Finger 1 (MZF1), and present reasoning for its potential targeting in cancer and discuss
the possibilities of how to target it.
2. What Is MZF1?
2.1. MZF1 Is a Sequence-Specific, Oncogenic Transcription Factor Involved in Myeloid Differentiation
MZF1 is a member of the SCAN domain-containing zinc finger transcription factor (SCAN-ZFP)
family, a subfamily of zinc finger proteins (ZFPs)[3]. SCAN-ZFPs represent a class of DNA-binding
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proteins, many of which are known to regulate transcription during different developmental processes.
MZF1 was first isolated from the peripheral blood from a patient with chronic myeloid leukemia and
was described as a novel zinc finger protein involved in transcriptional regulation of hematopoietic
development [4]. A few years later it was shown to regulate the expression of hematopoiesis-specific
genes influencing differentiation, proliferation and programmed cell death and its aberrant expression
was found to result in the development of hematopoietic cancers [5,6]. During the last decade, MZF1
was shown to be implicated in the development of various types of solid cancers by enhancing cancer
cell growth, migration and invasion [7–15]. Knowledge on the detailed mechanisms by which MZF1
activity is regulated and the central target genes it activates has steadily increased and is still emerging
due to active research on the topic.
2.2. MZF1 Transcript Variants and Functional Domains
MZF1 is encoded by a single-copy gene located at chromosome 19q13.4, which is the sub-telomeric
region of the chromosome 19q, containing a large number zinc finger genes [4]. Full-length MZF1
protein is estimated to be about 82 kD without post translational modifications. MZF1 gene supposedly
encodes three transcript variants, which are predicted to result from alternative use of two transcription
initiation sites and from alternative splicing [16,17]. MZF1 gene is composed of six exons [16,17]. Early
work on MZF1 transcripts lead to the identification of two human MZF1 isoforms: one full-length
734 amino acid isoform containing a SCAN domain in the N-terminus; 13 zinc finger DNA-binding
domains in the C-terminus; and one N-terminally truncated, 485 amino acid isoform containing the 13
zinc finger DNA-binding domains and a short N-terminal fragment [16,17] (Figure 1).
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collectively denoted as MZF1. A third MZF1 isoform of 290 amino acids containi g o ly the SCAN
domain in the N-terminus was later identified by the National Institute of Health Mammalian Gene
Coll cti n Program (http://genecoll ctions.nci.nih.gov/MGC/) (Figure 1). This so-called “SCAN domain
only” isoform belongs to a group of proteins known as SCAND proteins. SCAND proteins are expected
to function as regulators of other SCAN domain-containing proteins [19,20]. The tissue-specific
expression and function of this isoform has not been elucidated. It also needs to be noted that the
485 amino acid “zinc finger only” isoform of MZF1 has been recently deleted from the human NBCI
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sequences and replaced with the predicted sequence of 450 amino acids “zinc finger only” form, where
the N-terminus is slightly shorter than in the 485 amino acids form (Figure 1).
Full-length MZF1 consists of five distinctive domains (Figure 1). The domain furthest towards the
N-terminus is called an acidic domain (A), which is rich in glutamic and aspartic acid [16,21]. This
domain is involved in transcriptional activation and contains regulatory SUMO and phospho-sites [22].
It can also mediate interactions between MZF1 and other transcription factors [22–24]. Downstream
of the acidic domain is the SCAN domain of 84 amino acids, a leucine-rich region known to mediate
protein–protein interactions [16,17,25,26]. The SCAN domain is found in the SCAN-ZFP family of zinc
finger proteins and it mediates homo- and heterodimer formation between SCAN domain containing
zinc finger proteins [25–28]. Following the highly conserved SCAN domain there is a so-called
transcriptional activation domain (TAD). It is a serine and threonine rich region that is involved in the
transcriptional activation of MZF1 [18,21]. This MZF1 domain was identified as a TAD by a classical
study by Ogawa and co-workers [21]. In the study, they showed that in murine MZF1 this domain is
phosphorylated by mitogen-activated protein kinase ERK and p38 in three of its serines, serine 257,
275 and 295, leading to transcriptional inactivation of Mzf-2a. Consequently, substitution of all of
these serines with alanines resulted in strong enhancement of its transcriptional activity in murine
myeloid cell line LGM-1[21]. The corresponding sites are conserved in human MZF1, where they are
represented as serine 256, 274 and 294. Later on, post-translational modifications in both the acidic
domain and the SCAN domain were found to contribute to the transcriptional activity of human
MZF1 [22]. In the C-terminal region of MZF1 are the 13 highly conserved Krüppel-like zinc finger
motifs arranged in two domains. The first four zinc-finger motifs form one zinc-finger domain and the
last nine motifs form another zinc-finger domain, separated from the first one by a glycine-proline-rich
region of 24 amino acid residues [4] (Figure 1). The two zinc-finger domains of MZF1 bind to two
distinct, yet similar DNA consensus sequences with a common core sequence of four or five guanines,
which allows MZF1 to bind more than one DNA sequence at the same time [29], or to bind stronger in
genomic sites containing binding sites for both motifs.
3. MZF1 and Cancer
3.1. MZF1 and Hematological Malignancies
MZF1 was originally isolated from chronic myeloid leukemia and was shown to be involved
in hematopoietic differentiation due to its ability to control the expression of genes involved in
hematopoiesis such as CD34 and MYB [4–6]. Due to these reasons, most of the earliest studies on the
function of MZF1 were done in hematopoietic cells. Some of the results concerning the actual role
and function of MZF1 in hematopoietic malignancies are contradictory. This is because during the
earliest studies of MZF1, the knowledge of MZF1 isoforms was not complete. Thus, many studies were
done using overexpression of the so-called zinc-finger-only isoform of MZF1, that was the 485 amino
acid isoform (Figure 1), which is practically missing most of the N-terminal regulatory domains.
As mentioned, this zinc-finger-only isoform was later deleted from the human NBCI sequences,
suggesting that it may be a cloning artifact. It has, however, been replaced with a slightly shorter,
450 amino acid isoform, which is a predicted alternative MZF1 transcript that can theoretically exist.
In brief, early experiments involving overexpression of the 485 amino acid zinc-finger-only isoform in
myeloid cells showed that it inhibits hematopoietic differentiation of mouse embryonic stem cells and
delays retinoic acid-induced granulocytic differentiation and apoptosis by inducing proliferation in
human promyeloblasts [6,30]. Contrary to what would be expected from these overexpression studies,
silencing of MZF1 with antisense oligodeoxynucleotides (AOS) significantly inhibited granulocyte
development in vitro from granulocyte colony-stimulating factor-induced cells originating from normal
bone marrow, which was evident from granulocyte colony formation assays [31]. This result coincides
with the results obtained from Mzf1 knockout mice, which accumulate highly proliferating myeloid
cells in their bone marrow and liver, disturbing the tissue architecture, indicating that Mzf1 may
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function as a tumor suppressor in the hematopoietic compartment [32]. Since AOS and knockout
studies target the full-length MZF1, it is understandable that the results obtained when downregulating
or inhibiting MZF1 expression would not necessarily be the opposite of the results obtained when
overexpressing the MZF1 zinc-finger-only isoform. The zinc-finger-only-isoform, by lacking the
N-terminus that contains most of the regulatory domains of MZF1, would have impaired regulation
of its activity and would be unable to dimerize with SCAN domain-containing proteins. However,
it could mimic MZF1 in a potential state where it is void of its upstream regulation. This could be
achieved for example via cancer-induced aberrant expression of MZF1. Thus, it can be concluded that
aberrant expression and regulation of MZF1 can make it oncogenic, which is also supported by the fact
that mouse embryonic fibroblasts that overexpress the zinc-finger-only MZF1 isoform form aggressive
tumors in athymic mice and lose their contact inhibition and upregulate their growth ex vivo [33].
3.2. MZF1 Acts as an Oncogene in Solid Cancers
Several studies demonstrate that MZF1 can promote tumorigenesis of various solid cancers. These
include breast, cervical, colorectal, liver, lung, and prostate cancer [7–9,11–15,34]. Many MZF1 target
genes have a central role in cancer, and increased expression and/or activation of MZF1 induces cell
growth, migration and invasion [7–15]. Below we will summarize most of the results obtained on
MZF1 in some common solid cancers.
3.2.1. MZF1 in Breast Cancer
MZF1 is needed for the invasion of ErbB2-expressing breast cancer cells [7]. In a study by Rafn
and co-workers, ErbB2 activation was shown to induce the invasion of breast cancer cell spheroids via
activation of a signaling network that involves TGFβ receptor 1 and 2 (TGFBR1 and 2), ERK2 (MAPK1),
PAK4, PAK5 and PAK6 (PAK4, PAK5 and PAK6), cdc42 binding protein kinase beta (CDC42BPB),
and protein kinase Cα (PKCα; PRKCA). Activation of this signaling network leads to activation
of MZF1 and MZF1-mediated induction of expression of lysosomal cysteine cathepsins B and L
(CTSB and CTSL1). This work implied for the first-time involvement of lysosomes in the invasion
of ErbB2-expressing cancer cells. It showed that MZF1, upon activation by ErbB2 signaling, can
induce the pericellular accumulation of lysosomes at the invadosome-like cellular protrusions in
invasive ErbB2 expressing breast cancer cells, thereby initiating and promoting their invasion [7].
Once lysosomes have travelled to the cell periphery, their hydrolytic content can be secreted into the
extracellular space (lysosomal exocytosis). This can initiate and induce invasion mainly via cathepsin
B, which cleaves and thereby activates matrix metalloproteases (MMP) 2 and 3 and the urokinase
plasminogen activator [35–37]. Consistently, ErbB2-positive primary breast tumors exhibit increased
mRNA and protein expression of cathepsins B and L. Supporting the in vivo connection of ErbB2
activation and cathepsins B and L, the positive correlation between ErbB2 and cathepsin B and L
expression in invasive breast cancer was found to be significant [7].
Interestingly, MZF1 regulates the expression of TGFβ1 gene (TGFB1) in response to
osteopontin-induced integrin signaling in human mesenchymal stem cells, where increased TGFβ
signaling induces them to differentiate and adapt a cancer-associated fibroblast phenotype, a process
that leads to increased tumor growth and metastasis [14]. TGFβ1 is considered as one of the main
regulators of epithelial mesenchymal transition (EMT) [38] and ErbB2 overexpression is connected
to TGFβ overexpression, secretion and activation of TGFβ signaling [39]. TGFβ signaling amplifies
oncogenic ErbB2 signaling and promotes invasion and metastasis of ErbB2 positive cancer cells [40–42].
Since ErbB2-induced activation of MZF1 is enhanced by TGFβ receptor signaling and TGFB1 is a
MZF1 target gene, increased TGFβ signaling can further induce ErbB2 signaling via a feedback loop
involving MZF1 activation. This may additionally lead to enhanced activation of other MZF1 target
genes that are important for amplification of breast cancer signaling networks and promoting breast
cancer cell migration and invasion, such as PRKCA [11]. Interestingly, a complex formation between
Elk-1 and MZF1 has been shown to enhance PRKCA expression in a synergistic manner and its
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expression correlates positively with the expression of Elk1 and MZF1 in various breast cancer cell
lines [11]. Moreover, a high level of MZF1 in triple-negative breast cancer cell lines Hs578T and
MDA-MB-231 is associated with a mesenchymal phenotype with increased cell migration and invasion,
which is mediated via insulin-like growth factor receptor (IGF1) [24]. Consequently, destabilization
of MZF1 by the IGF1R-driven p38MAPK-Erα-SLUG-E-cadherin pathway leads to conversion of the
invasion-promoting mesenchymal phenotype to the less invasive epithelial phenotype. In osteoblasts,
which are involved in osteolytic breast cancer metastasis, MZF1 has been shown to upregulate the
expression of another EMT regulator, N-cadherin (CDH2) [43]. Moreover, a MZF1 target gene AXL,
which can be activated upon lapatinib resistance in ErbB2 positive breast cancer cells [44], has been
shown to induce EMT in breast cancer cells [45]. This all suggests that MZF1 has a role in the
development of aggressive breast cancer.
3.2.2. MZF1 in Cervical and Colorectal Cancers
MZF1 activation has been implicated in the progression of cervical and colorectal cancer, where it
increases invasion and metastasis, at least partially, via increased expression and activity of receptor
tyrosine kinase AXL [8]. Increased expression of AXL has been connected to invasion and metastasis
of many types of cancers [45–47]. Supportively, both MZF1 and AXL protein levels are considerably
higher in colorectal tumors than in corresponding normal tissue [8]. MZF1 binds directly to the AXL
promoter, leading to increased AXL mRNA and protein expression [8]. However, depletion of AXL by
RNA interference only partially inhibits MZF1-induced migration and invasion of colorectal cancer
cells, suggesting that additional MZF1-regulated genes are involved in this process. MZF1 is also
central for the activation of the expression of Phosphoinositide -3-Kinase Regulatory Subunit 3 Gamma
(PIK3R3), which is a regulatory subunit of PI3 kinase (PI3K) needed for PI3K signaling and is important
for cancer cell proliferation [15]. In human papillomavirus infected cervical cancer, MZF1 induces
the expression of another transcription factor, NKX2-1, which in turn upregulates a cancer stem cell
regulator FOXM1, resulting in increased tumor growth and invasion [48]. In another study with
SiHa human cervical cancer cells, MZF1 was shown to bind the matrix metalloprotease 2 (MMP2)
promoter, and a bit surprisingly to suppress its expression, and thus was reported to function as a
tumor suppressor in these cells [49].
3.2.3. MZF1 in Liver and Lung Cancer
MZF1 regulates the expression of the PKCα gene, PRKCA, in human hepatocellular carcinoma
cells, where it binds directly to the MZF1 binding site in the PRKCA promoter region [9,12]. Depletion
of MZF1 with specific antisense oligonucleotides reduces proliferation, migration and invasion of
hepatocellular carcinoma cells [9,12] and suppresses the growth of the corresponding xenografts [10,12].
In lung cancer, MZF1 activates the expression of the c-Myc gene (MYC) upon loss of the liver kinase B1
(LKB1) [13]. This results in enhanced migration and invasion of lung cancer cells and facilitates their
growth in soft agar [13]. In tumors from lung adenocarcinoma patients there is a positive correlation
between high MYC and MZF1 and low LKB1 expression. Importantly, lung adenocarcinoma patients
with low LKB1 expression have a shorter overall survival than patients with high LKB1 expression [13].
In lung cancer, MZF1 can upregulate the expression of NKX2-1, which in turn increases the expression
of FOXM1 resulting in facilitated tumor growth and invasion [48]. On the other hand, in lung
adenocarcinomas, the loss of LKB1 is associated with NKX2-1 expression [50].
3.2.4. MZF1 in Prostate Cancer
The role of MZF1 in prostate cancer is somewhat more complicated. The expression of the cell
division control 37 (CDC37) gene is increased in prostate cancer cells. Here, MZF1 was shown to
bind to the promoter of CDC37 and upregulate its expression [51]. As expected, depletion of MZF1
in prostate cancer cells decreases CDC37 expression and reduces their tumorigenesis. Interestingly,
SCAND1, a SCAN domain protein that can inhibit MZF1 by dimerizing with it, can upon overexpression
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accumulate at the MZF1 binding sites at the CDC37 promoter and downregulate its expression-inhibiting
tumorigenesis [51]. On the contrary, MZF1 was shown to have the opposite effect in PC3 and DU145
prostate cancer cells, where expression of MZF1 upregulated ferroportin (FPN), the only known
mammalian iron exporter [52]. Depletion of MZF1 was found to decrease the expression of FPN, as
expected, but in turn this was shown to result in enhanced cancer cell growth in addition to increased
cytoplasmic iron retention [52]. Consequently, increase in the expression of MZF1 inhibited tumor
growth, suggesting that in respect to FPN regulation in these prostate cancer cells, MZF1 can exhibit a
tumor suppressor type of function.
3.2.5. MZF1 in Other Type of Cancers
In glioma cell lines, MZF1 binds directly to the LIM-only protein 3 (LMO3) promoter and induces
the expression of LMO3 [53], which is a transcriptional co-activator that can act as an oncogene in
glioma, one of the most aggressive and most common tumors of the central nervous system. LMO3 is
often overexpressed in gliomas and its expression correlates positively with poor prognosis [53]. The
19q chromosomal deletions together with the deletion of 1p are used to define the oligodendroglioma,
which is a specific type of glioma with favorable prognosis and good response to chemotherapy [54].
Interestingly, the 19q chromosomal deletions in oligodendroglioma include the MZF1 locus as well as
the locus of genes coding for many other zinc-finger proteins. In esophageal squamous cell carcinoma
samples of 13 patients, MZF1 was found to be co-activated with three other transcription factors, SPIB,
MAFG and NFE2L1 when compared to their paired non-cancerous tissues using microarray analysis,
where the expression of 17 other transcription factors was suppressed [55]. In gastric cancer cells,
MZF1 upregulates MMP14 expression by directly binding to its promoter [56]. In the same study it
was shown that in the clinical samples, MZF1 expression correlated positively with MMP14 expression
in gastric cancer. On the contrary to this, another study where human gastric cancer samples were
analyzed indicated that MZF1 expression was decreased during gastric cancer progression, which
correlated with increased invasiveness of gastric cancer [57].
3.2.6. Many MZF1 Target Genes Have a Role in Cancer
MZF1 exerts its activity via modulating the expression of its target genes. Aberrant MZF1
expression and activation results in transcriptional changes that increase cell growth, migration and
invasion (see above and reviewed by Eguchi and co-workers [58]). In summary, MZF1 may promote
invasion and migration partially by controlling the expression of kinases that are controlling these
processes such as AXL and PRKCA. It can also increase expression of lysosomal, invasion-inducing
and promoting hydrolases CTSB and CTSL1, which facilitate intra- and extracellular degradation of
extracellular matrix components by their direct cleavage or by indirectly cleaving and activating matrix
metalloproteases MMP2 and MMP3 and urokinase plasminogen activator, which in turn degrade the
extracellular matrix [35,36]. MZF1 is also expected to have a role in EMT by controlling the expression
of TGFB1, CDH2 and FOXM1, and several other EMT-related genes. In Table 1, we have listed the
known MZF1 target genes. However, it needs to be noticed that only the ones that are verified by
chromatin immunoprecipitation can be considered definite direct targets of MZF1.
Table 1. MZF1 target genes; their method of identification (ChIP: chromatin immunoprecipitation;
EMSA: electrophoretic mobility shift assay), reference, function (the role of MZF1) and their involvement
generally in EMT (yes, if involvement has been reported).
Gene Method Reference Function EMT
AXL ChIP, Luciferase [8] Activator yes
CD14 EMSA,luciferase [59] Activator yes
CD34 EMSA, Acetyltransferase activity [6] Activator
CDC37 ChIP, Luciferase [51] Activator
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Table 1. Cont.
Gene Method Reference Function EMT
CDH2 (N-Cadherin) EMSA [43] Activator yes
CDH2 (N-Cadherin) ChIP, Luciferase [60] Activator
CK17 Luciferase, qPCR [61] Activator
CTGF ChIP [62] Activator yes
CTSB ChIP, Luciferase [7] Activator
GAPDH ChIP [63] Activator yes
HK2 ChIP [64] Suppressor
IGFIR ChIP, Luciferase [65] Suppressor yes
ITGAM (CD11b) EMSA, luciferase [59] Activator
LMO3 ChIP [53] Activator
MMP2 ChIP, Luciferase [49] Suppressor yes
Mtor ChIP, EMSA, Luciferase [66] Suppressor yes
MYB (c-myb) EMSA, Acetyltransferase activity [6] Activator
MYC ChIP, Luciferase [13] Activator
NFKB1A ChIP [67] Activator yes
NKX2-1 ChIP, Luciferase [48] Activator yes
NKX2-5 ChIP, Luciferase [68] Activator yes
NOV ChIP [61] Activator
OOCT4 Luciferase [69] Activator yes
PAX2 Luciferase [70] Suppressor yes
PIK3R3 (p55PIK) ChIP, Luciferase [15] Activator yes
PRAME ChIP [71] Activator yes
PRKCA (PKC alpha) ChIP, Luciferase [12] Activator
SLC40A1 (FPN) ChIP, Luciferase [52] Activator
SMAD4 ChIP, EMSA, Luciferase [72] Activator
TGFB1 ChIP, Luciferase [73] Activator yes
TNFRSF10B (DR5) Luciferase [74] Activator
YAP1 ChIP, EMSA, Luciferase [75] Activator yes
4. How Does MZF1 Function?
In order to target the oncogenic functions of MZF1, we need to understand how MZF1 is regulated.
The key to MZF1 function in cancer lies in its domain structure and in its post-translational modifications
(Figure 2) that are regulating its association with other factors, its activation status and its availability.
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SLC40 1 (FPN) ChIP, Luciferase [52] ctivator  
SMAD4 ChIP, EMSA, Luciferase [72] ti ator  
TGFB1 ChIP, Luciferase [73] Activator yes 
TNFRSF10B (DR5) Luciferase [74] ctivator  
YAP1 ChIP, EMSA, Luciferase [75] ti ator yes 
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4.1. Regulation of MZF1 Expression
Relatively little is known about the transcriptional regulation of MZF1. Originally, MZF1 was
identified as an important transcriptional regulator of myeloid differentiation, and its expression
was believed to be myeloid-specific [76]. Later on, it was identified as an oncogenic transcription
factor responsible for migratory and invasive phenotypes of various cancer cell lines. Analysis of
TCGA website data indicates that there is a significant amplification of the MZF1 gene in various solid
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cancers [58]. These include breast, bladder, lung, and uterine cancers. Indeed, increased expression of
MZF1 protein levels has been detected in the study of 321 tissue microarray samples containing primary
breast cancer and normal breast samples [77]. In these samples, MZF1 levels were shown to significantly
increase from normal breast tissue to grade 1–2 tumors, which define invasive ductal carcinoma.
Non-coding RNAs have arisen as important regulators of gene expression. Several microRNAs
(miRNAs) can regulate MZF1 expression. Let-7 miRNAs belong to the group of miRNAs whose
aberrant expression is most frequently associated with cancer [78]. Let-7 is upregulated during
differentiation, and its expression is systematically downregulated in malignant cancers including
breast cancer [79]. Let-7 binds to the 3′-untranslated region of MZF1, and ectopic expression of
let-7 microRNAs let-7d and let-7e can efficiently downregulate MZF1 and invasion of constitutively
active ErbB2-expressing breast cancer cells [77]. MiR-492 is another microRNA that can bind to the
3′-untranslated region of MZF1 [52]. MiR-492 regulates MZF1 expression in prostate cancer cells,
and in prostate tumors, miR-492 levels correlate reversibly with the levels of MZF1. Another study
with glioma cell lines indicates that overexpression of miR-101 leads to a decrease in MZF1 expression,
without going further into detail in regard to its potential binding sites in MZF1 [53]. MiRNA-337-3p
inhibits gastric cancer progression by downregulating MZF1 activity via a specific mechanism, where
miRNA-337-3p binds to the promoter region of MMP14 adjacent to its MZF1 binding site and represses
the MZF1-induced expression of MMP14 [56]. Consequently, in the same study, miRNA-337-3p was
shown to inhibit growth, invasion, metastasis, and angiogenesis of gastric cancer cells in vitro and
in vivo via repression of MZF1 activity. Furthermore, miRNA-337-3p expression was found to be an
independent prognostic factor for a favorable outcome in gastric cancer.
Interestingly, according to UCSC genome browser (https://genome.ucsc.edu), a validated long
non-coding RNA exists that contains the whole MZF1 coding sequence resulting in 15,573 base pair
antisense RNA (LOC100131691). Thus far, no studies exist of its actual regulation, expression or
function, although it is tempting to speculate that it can have a regulatory role in the expression
of MZF1.
4.2. Regulation of the Transcriptional Activity of MZF1
4.2.1. Interaction with Other Transcription Factors
MZF1 has to dimerize to function as a transcription factor. MZF1 utilizes its SCAN domain to
form homo- and heterodimers with other SCAN-domain transcription factors [25–28]. The possibility
of heterodimerization via the SCAN domain exposes MZF1 to an additional level of regulation,
since depending on its dimerization partner, MZF1 may function as a transcriptional activator or
repressor. Known SCAN domain-containing MZF1 dimerization partners include SCAN-ZFP family
members RAZ1, ZNF24, ZNF174, and ZNF202 [3,26,80], which are all heterodimerizing with MZF1 via
a SCAN–SCAN interaction. A recent computational study has tried to shed new light on MZF1 SCAN
domain interactions by identification and analysis of cancer-specific mutations in the MZF1 SCAN
domain [81]. In this study, 23 cancer-specific mutations were identified in the MZF1 SCAN domain,
which could affect MZF1 function by changing its dimerization capacity directly or indirectly via gain
or loss of possible post-translational modifications (Nygaard et al., 2016). This work identified cysteine
69 as a potential regulator of MZF1 SCAN–SCAN interactions. Moreover, simultaneous expression
and appearance of other SCAN and SCAND domain-containing proteins and possible cancer-inducing
mutations in them could also affect MZF1 function for example by directly or indirectly replacing the
binding partners of MZF1. However, this type of exiting regulation scheme is still mostly theoretical,
especially in the case of MZF1 heterodimers, since detailed biological information on the specific
regulation of the transcriptional activity of MZF1 via heterodimeric SCAN–SCAN interactions is
still missing.
In addition to SCAN-domain proteins, MZF1 can interact with proteins without the classical
SCAN domain, which complicates the scenario of its regulation by binding partners. Moreover, MZF1
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interaction with other proteins can even occur via other domains than the SCAN domain. Recent work
has indicated that the acidic domain of MZF1 is an additional protein–protein interaction domain. The
acidic domain of MZF1 is involved in its association with Elk1 in triple negative breast cancer [12,23,24].
Association of MZF1 and Elk1 via the acidic domain of MZF1 and the heparin-binding domain of
Elk1 increases invasion, migration and mesenchymal phenotype of breast cancer cells. This occurs via
increasing the expression of PRKCA and IGF1R by direct binding of MZF1 to their promoter regions. In
non-invasive MCF7 breast cancer cells, MZF1 interacts with the CCCTC-binding factor (CTCF) via its
acidic domain, which results in downregulation of the transcriptional activity of MZF1 [22]. Activation
of ectopic ErbB2 signaling results in SUMO-directed (SUMOylation of lysine 23) phosphorylation of
MZF1 serine 27 at its acidic domain, which dissociates MZF1 from its transcriptional repressor CTCF,
allowing transcriptional activation of MZF1 [22].
4.2.2. SUMOylation of MZF1
The activity of transcription factors can be modulated by covalent attachment of small
ubiquitin-related modifier (SUMO) proteins: SUMO1, SUMO2, SUMO3, and SUMO4 in their SUMO
acceptor sites [82]. According to current knowledge of consensus SUMOylation sites, MZF1 has three
predicted SUMOylation sites: lysine 23, 184 and 146 (Figure 2) [22,58]. An earlier study that was the
first to report MZF1 SUMOylation, suggested that a SUMOylation site would reside in the amino
terminus of MZF1 between amino acids 15–27 [80], which is a conserved sequence found in a subset
of SCAN-ZFPs [19,80]. This site was identified by showing that overexpressed full-length MZF1 has
the ability to accumulate into promyelocytic leukemia nuclear bodies (PML-NBs), a function which
requires SUMOylation, and which could be abolished when this area was deleted from MZF1 [80].
SUMOylation of transcription factors and their cofactors may lead to transcriptional activation
or inactivation [82,83]. Several studies suggest an important role of PML-NBs in transcriptional
regulation [84,85]. Especially, PML-NBs has been presented as a site where SUMO-conjugation occurs
and where SUMOylated nuclear proteins reside and accumulate [86]. PML-NBs usually associate to
the areas of genomic regions with high transcriptional activity, and many transcription factors can be
transiently recruited to PML-NBs. Since SUMOylation usually occurs in the nucleus [83], introduction
of mutations in the nuclear SUMO-modified proteins that interfere with their SUMOylation can
promote their translocation into the cytoplasm. Thus, MZF1 SUMOylation may be involved in its
nuclear retention and its ability to function as a transcription factor.
MZF1 lysine 23 has been identified as a SUMOylation site that directly regulates the transcriptional
activity of MZF1 [22]. Its occupation by SUMO groups exposes a nearby serine 27 for phosphorylation
by PAK4 in response to ErbB2 activation, which in turn results in increased transcriptional activity of
MZF1, indicating its importance for the transcriptional activation of MZF1 as well as defining a new
mechanistic type of post-translational regulation, “SUMO-directed phosphorylation”. In the same
study, lysine 184 was mapped as an additional functional SUMO acceptor site. However, no biological
function has yet been identified for it. It is tempting to speculate that MZF1 SUMOylation may be
regulating its stability. However, in our studies of MZF1 post-translational modification and their
effect on protein stability, we found that in ErbB2-expressing breast cancer cells, MZF1 is a very stable
protein and its stability was not affected by mutating its SUMO sites (Brix and Kallunki, unpublished
observations). Moreover, in the ErbB2-expressing breast cancer cells, no evidence of SUMOylation
of lysine 146 was found [22]. It is possible that lysine 146 is not a functional SUMO acceptor site in
MZF1. Supporting this, its probability as a SUMO acceptor site is much lower than that of lysine 23
and 184 [22,58].
4.2.3. Phosphorylation of MZF1
MZF1 is a phosphoprotein that contains several potential as well as functional phosphorylation
sites. Even though its massive phosphorylation has been known for some time, thanks to the large
amount of phosphorylation analysis done by Mass Spectrometry that has been deposited on the web
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(http://www.phosphosite.org), thus far no biological function has been shown for the majority of these
sites. In a study conducted in MCF7 breast cancer cells with inducible expression of constitutively
active ErbB2, ErbB2 activation was shown to increase the transcriptional activity of MZF1 via a
signaling network that involves TGFβ receptors 1 and 2 (TGFBR1 and 2), ERK2, PAK4 (PAK5 and
PAK6), cdc42 binding protein beta kinase (CDC42BPB), and PKCα (PRKCA) [7]. In a recent study
that utilized ErbB2 positive breast cancer cells for phosphorylation analysis by Mass Spectrometry,
13 MZF1 phosphorylation sites were identified [22]. Only three of these were phosphorylated in
response to ErbB2 activation. These were serine 27, serine 162 and threonine 177, other sites being
constitutively phosphorylated. Of these three sites, only phosphorylation of serine 27 was shown
to increase the transcriptional activity of MZF1, the two others having no significant effect on it [22].
Supporting the importance of this phospho-site in vivo, serine 27 phosphorylation was found in an
ErbB2-positive breast tumor sample in a proteomics study covering 105 breast tumors that were
characterized for TCGA [87]. Furthermore, MZF1 serine 27 phosphorylation was found to correlate
positively and significantly with ErbB2 status in a breast tumor tissue microarray containing 225 tissue
cores embedded as duplicates and enriched with primary invasive breast cancer samples [22]. The
phosphorylation of serine 27 is tightly connected to the SUMOylation of lysine 23 through a mechanism
where SUMOylation of lysine 23 is needed as a prerequisite for the phosphorylation of serine 27 by
PAK4. In silico modelling of this activation mechanism suggests that SUMOylation of lysine 23 opens
up and exposes the serine 27, which otherwise is masked and not approachable for PAK4 to dock
to it and phosphorylate it (Figure 3). Phosphorylation of serine 27 will then dissociate MZF1 from
the transcriptional repressor CTCF, allowing MZF1 to activate transcription of CTSB needed for the
invasion of ErbB2-expressing cells. Interestingly, a recent study in human esophageal cancer cell lines
demonstrated that phosphorylation of MZF1 serine 27 by constitutively active casein kinase 2 (CK2),
which is often upregulated in cancers, mediates their epithelial to mesenchymal transition by inducing
the expression of N-cadherin [60].
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Figure 3. Graphical presentation of MZF1 activation and induction of CTSB expression in
lysosome-mediated invasion as a response to ErbB2 signaling. ErbB2 activation, further supported by
activation of TGFβ signaling, activates ERK2 and PAK4. Active PAK4 will phosphorylate MZF1 serine
27, if its adjacent lysine 23 is SUMOylated, which exposes MZF1 serine 27 to PAK4 phosphorylation. As
a response to phosphorylation of serine 27, MZF1 association of its transcriptional repressors, e.g., CTCF,
is prevented and MZF1 can now activate CTSB expression and lysosome redistribution, which leads to
lysosome-mediated invasion.
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4.2.4. Mutations Creating New MZF1 Binding Sites in the Genome
Cancer-induced somatic mutations can create new transcription factor binding sites at the
regulatory regions of cancer genes [88]. Mutations at the promoter regions of genes that are important
for cancer progression can create new transcription factor binding sites that can contribute to the
overexpression of that particular gene. Tian and co-workers have identified a mechanism by which
MZF1 can affect gene expression via cancer-induced allelic mutations that result in a novel transcription
factor co-operation at the promoter of the hepatocyte growth factor gene HGF [89]. They have identified
single-nucleotide polyformism (SNP) and single nucleotide variants (SNV) in multiple myeloma at
the promoter region of HGF that result in its increased expression. These mutations resemble the
wild-type sequences of the binding motifs of MZF1, nuclear factor kappa-B (NFκB) and nuclear factor
erythroid 2-related factor 2 (NFR-2), which together can contribute to increased expression of HGF.
Whether this is a single type of cancer and a gene where new MZF1 binding sites are gained through a
cancer-induced mutation or if multiple cancers and promoters are involved, is not yet known.
5. How Does MZF1 Promote Cancer Invasion and Metastasis?
The mechanistical explanations of how MZF1 promotes cancer progression must rely on the
activation of its specific target genes in cancer. Currently known MZF1 target genes have been mapped
in individual functional studies, however, no genome-wide studies on MZF1 transcriptional targets
have been reported. The majority of the known MZF1 target genes are known cancer genes, whose
activation is expected to promote cancer progression (Table 1). Two of the invasive processes activated
by MZF1 have been described in more detail. We will briefly present these below.
5.1. Lysosomes, MZF1 and Invasion
Lysosomes have a central role in the induction of invasion by ErbB2 in breast cancer cells [90].
Invasion of the MCF7 breast cancer spheroids expressing the trastuzumab-resistant p95 form of
ErbB2 depends on the activation of a signaling network that culminates in the activation of MZF1 [7].
Here MZF1 regulates the function and activity of lysosomes by mediating ErbB2-induced, increased
expression of lysosomal cysteine cathepsins B and L (CTSB and CTSL1), which is necessary for the
invasion of these cells. Increased expression of CTSB and CTSL1 leads to increased activity of cathepsins
B and L, whose expression correlates positively (p < 0.0001) with high ErbB2 status in primary invasive
breast cancer [7]. This is connected to the redistribution of lysosomes from a perinuclear to a peripheral
position in invadosome-like cellular protrusions adjacent to the cell membrane, which is induced by
phosphorylation of MZF1 serine 27 [22]. The appearance of the peripheral population of lysosomes
correlates positively with the invasiveness of ErbB2 positive ovarian and breast cancer cells [7,91] and
can contribute to extracellular matrix (ECM) degradation both internally and externally [34,36,37].
Peripheral lysosomes degrade the ECM components that have been internalized by the cell. Moreover,
they can secrete their hydrolytic content, including cathepsin B, into the extracellular space to initiate
and promote invasion. Secreted cathepsin B degrades the ECM components type IV collagen, laminin,
and fibronectin and initiates the activation of the extracellular degradome by cleaving the pro-forms
of urokinase plasminogen activator and MMP2 and MMP3 [92], which are activators of MMP9 and
MMP13 (Figure 4). MZF1 seems to be a central regulator of invasion-associated pericellular lysosome
distribution and lysosome-mediated invasion of ErbB2 expressing highly invasive cancer cells [7,22,90]
(Figure 3).
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5.2. MZF1 and EMT
Recently, MZF1 has been connected to E T, a biological process where epithelial cells lose their
polarity and cell–cell adhesion capability and gain invasive and migratory properties by adapting a
mesenchymal phenotype. In human esophageal cancer cell lines, phosphorylation of MZF1 serine
27 by CK2 initiates EMT by inducing the transcription of N-cadherin during the EMT-inducing
switch from E-cadherin to N-cadherin [60]. Knockdown of MZF1 by specific shRNA reverses the
mesenchymal phenotype of these cells into epithelial and downregulates the expression of N-cadherin.
In triple-negative breast cancer cells, MZF1 activation can maintain the mesenchymal phenotype by
interacting with Elk1 at the promoter region of IGF1R [24]. Even though evidence of the connection
between MZF1 and EMT is increasing, it is still not clear if the role of MZF1 in EMT is cancer
type-specific, or if MZF1 can have a more general role in the initiation and/or maintenance of EMT.
Intriguingly, 17 of the 31 (55%) reported MZF1 target genes (Table 1) are somehow involved in EMT in
other cancer studies.
6. Conclusions and Future Directions
The majority of studies on MZF1 in cancer report that MZF1 functions as an oncogene in various
solid cancers by regulating the expression of genes involved in cancer progression, EMT, extracellular
matrix degradation, invasion, and angiogenesis. Inhibition of MZF1 function could be a way to inhibit
these processes. Differe t efficient appro ches to inhib t transcrip ion fac or activity in cancer exist,
including transcription fac or d stab lization by affecting the post-translational modifications that
regulate sta lity or a tivity. Regarding MZF1, probably one of the most successful sce arios c uld
be to inhibit its association with its specific co-transcriptio factors such as Elk1, which is needed for
MZF1-induced activation of the expression of PRKCA and IGF1R, and which contributes to the stability
of MZF1 in triple-negative breast cancer [24].
Specific post-translational modifications of MZF1 are induced in invasive cancer, as is the case
for breast cancer harboring ErbB2 activation, and these are necessary for the invasive signaling
mediated via MZF1 in response to ErbB2 activation in breast cancer cells [22]. Thus, another valid
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possibility would be to target the enzymes responsible for these post-translational modifications,
namely SUMOylation of lysine 23 and/or phosphorylation of serine 27. It is not known what regulates
the SUMOylation of lysine 23, which is a prerequisite of the phosphorylation of serine 27 by PAK4 [22].
However, a theory exists according to which the generally high phosphorylation status of MZF1,
and especially the phosphorylation of serine 8 can bend the MZF1 molecule to a position where
lysine 23 is exposed to SUMOylation [22,81]. Interestingly, increased SUMOylation is generally
connected to cancer progression, and in breast cancer it is associated with poor prognosis [93,94].
The expression of SUMOylation-associated enzymes is often increased in cancer, and thus, numerous
SUMO-pathway-targeting inhibitors have been developed, many of which can be considered as
promising anti-cancer agents [95]. These could also target SUMOylation of MZF1 lysine 23 and thus
prevent the activation of MZF1 by hindering the phosphorylation of serine 27.
PAK4, a kinase that can phosphorylate MZF1 serine 27 in response to ErbB2 activation, is
considered as a good target for the treatment of a variety of solid cancers including breast cancer, and its
inhibition for this purpose has been patented by Hoffman-La Roche and Genentech [96]. Although
the resulting PAK4 inhibitor PF-3758309 failed in phase I clinical trials [97], a new PAK4 inhibitor,
KPT-9274, has been developed (Karyopharm Therapeutics, USA), which is currently in phase I clinical
trials [98]. Identification of MZF1 as an oncogenic target of PAK4, whose activity is important for
invasiveness of ErbB2 positive breast cancer cells, suggests that PAK4 inhibitors might be useful for
the treatment of cancers whose aggressiveness depends on MZF1.
Another possible way to target MZF1 could be by preventing its binding to the regulatory regions
of its cancerous target genes. For this, more understanding of its DNA-binding specificity would be
needed. For example, since it has two distinct zinc finger domains with divergent binding sequences,
it would be useful to find out if either of them is a preferred binding domain for its target genes
that are important in cancer. Interestingly, by using CRISPR-Cas9 gene editing technology, we have
experienced that ErbB2-expressing breast cancer cell lines have developed dependency on MZF1,
so that these cancer cells harboring full knockout of MZF1 are not viable [22], suggesting that they
could have developed oncogene addiction towards MZF1. If this is the case, efficient inhibition of
MZF1 could result not only in inhibition of invasion but could also be lethal for them.
An increasing number of studies point to a central role for enhanced MZF1 expression and
activation in the invasiveness of different solid cancers, making it an attractive therapeutic target.
Several probabilities already exist for how its activity could be controlled, and at the same, interesting
possibilities still remain to be studied. One potentially useful future approach would be to carry
out an in silico screen to identify compounds that interfere with MZF1 DNA binding, dimerization
with specific partners or with post-translational modifications that are important for its activation.
Especially, its DNA binding domain as well as SUMOylation of lysine 23 and phosphorylation of serine
27 are well characterized. These modification sites are located in domains for which crystal structures
are available and would thus already be suitable for such an approach. To use this approach to identify
molecules that can prevent MZF1 heterodimerization, more research would be needed to understand
which associations are beneficial for cancer. In general, more research is still needed to increase the
understanding of the detailed function of MZF1 in cancer, of the cellular cancer-promoting programs it
regulates, the cancers where its inhibition would be most beneficial, and how it should be achieved.
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